칼리디 바이오테라퓨틱스(CLDI)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.19 (-6.30%), 시가총액 $0.00B, 52주 최저~최고 $0.17 ~ $7.25.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
칼리디 바이오테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
칼리디 바이오테라퓨틱스의 현재 주가는 $1.19 (-6.30%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
칼리디 바이오테라퓨틱스의 시가총액은 약 $0.00B입니다.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical